{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T19:10:01Z","timestamp":1751397001855,"version":"3.41.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-05738-y","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T18:29:09Z","timestamp":1751394549000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nomogram for the prediction of the prognosis of patients with triple-negative invasive ductal carcinoma of breast after neoadjuvant chemotherapy"],"prefix":"10.1038","volume":"15","author":[{"given":"Qiuyu","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangchen","family":"Xi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mudan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haosheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangzheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"5738_CR1","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.semcancer.2020.06.005","volume":"72","author":"F Borri","year":"2021","unstructured":"Borri, F. & Granaglia, A. Pathology of triple negative breast cancer. Semin. Cancer Biol. 72, 136\u2013145. https:\/\/doi.org\/10.1016\/j.semcancer.2020.06.005 (2021).","journal-title":"Semin. Cancer Biol."},{"key":"5738_CR2","doi-asserted-by":"publisher","first-page":"3514","DOI":"10.1002\/cncr.33629","volume":"127","author":"TC Poteat","year":"2021","unstructured":"Poteat, T. C. et al. Delays in breast cancer care by race and sexual orientation: Results from a national survey with diverse women in the United States. Cancer 127, 3514\u20133522. https:\/\/doi.org\/10.1002\/cncr.33629 (2021).","journal-title":"Cancer"},{"key":"5738_CR3","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1148\/radiol.211839","volume":"302","author":"LJ Grimm","year":"2022","unstructured":"Grimm, L. J., Rahbar, H., Abdelmalak, M., Hall, A. H. & Ryser, M. D. Ductal carcinoma in situ: State-of-the-art review. Radiology 302, 246\u2013255. https:\/\/doi.org\/10.1148\/radiol.211839 (2022).","journal-title":"Radiology"},{"key":"5738_CR4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/14737140.2021.1840984","volume":"21","author":"J Sukumar","year":"2021","unstructured":"Sukumar, J., Gast, K., Quiroga, D., Lustberg, M. & Williams, N. Triple-negative breast cancer: Promising prognostic biomarkers currently in development. Expert Rev. Anticancer Ther. 21, 135\u2013148. https:\/\/doi.org\/10.1080\/14737140.2021.1840984 (2021).","journal-title":"Expert Rev. Anticancer Ther."},{"key":"5738_CR5","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.3390\/ijms24032969","volume":"24","author":"NS van den Ende","year":"2023","unstructured":"van den Ende, N. S. et al. Triple-negative breast cancer and predictive markers of response to neoadjuvant chemotherapy: A systematic review. Int. J. Mol. Sci. 24, 2969. https:\/\/doi.org\/10.3390\/ijms24032969 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"5738_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17\u201348. https:\/\/doi.org\/10.3322\/caac.21763 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"5738_CR7","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.7314\/apjcp.2014.15.8.3555","volume":"15","author":"B Li","year":"2014","unstructured":"Li, B., Zhao, X., Dai, S. C. & Cheng, W. Associations between mammography and ultrasound imaging features and molecular characteristics of triple-negative breast cancer. Asian Pac. J. Cancer Prev. 15, 3555\u20133559. https:\/\/doi.org\/10.7314\/apjcp.2014.15.8.3555 (2014).","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"5738_CR8","doi-asserted-by":"publisher","first-page":"5901","DOI":"10.2147\/ijgm.S370351","volume":"15","author":"J Yin","year":"2022","unstructured":"Yin, J., Zhu, C., Wang, G. & Gu, J. Treatment for triple-negative breast cancer: An umbrella review of meta-analyses. Int. J. Gen. Med. 15, 5901\u20135914. https:\/\/doi.org\/10.2147\/ijgm.S370351 (2022).","journal-title":"Int. J. Gen. Med."},{"key":"5738_CR9","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1200\/jco.22.02572","volume":"41","author":"C Liedtke","year":"2023","unstructured":"Liedtke, C. et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol. 41, 1809\u20131815. https:\/\/doi.org\/10.1200\/jco.22.02572 (2023).","journal-title":"J. Clin. Oncol."},{"key":"5738_CR10","doi-asserted-by":"publisher","first-page":"11338","DOI":"10.12998\/wjcc.v10.i31.11338","volume":"10","author":"WX Lin","year":"2022","unstructured":"Lin, W. X. et al. Nomogram for predicting overall survival in Chinese triple-negative breast cancer patients after surgery. World J. Clin. Cases 10, 11338\u201311348. https:\/\/doi.org\/10.12998\/wjcc.v10.i31.11338 (2022).","journal-title":"World J. Clin. Cases"},{"key":"5738_CR11","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1186\/s40001-024-02139-1","volume":"29","author":"R Chen","year":"2024","unstructured":"Chen, R. et al. Does T1c\u20132N0-1M0 triple negative breast cancer derive a benefit from neoadjuvant chemotherapy?. Eur J Med Res 29, 599. https:\/\/doi.org\/10.1186\/s40001-024-02139-1 (2024).","journal-title":"Eur J Med Res"},{"key":"5738_CR12","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/jco.2007.14.4147","volume":"26","author":"C Liedtke","year":"2008","unstructured":"Liedtke, C. et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol. 26, 1275\u20131281. https:\/\/doi.org\/10.1200\/jco.2007.14.4147 (2008).","journal-title":"J. Clin. Oncol."},{"key":"5738_CR13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s10549-023-06959-3","volume":"200","author":"U Joshi","year":"2023","unstructured":"Joshi, U. et al. Clinical outcomes and prognostic factors in triple-negative invasive lobular carcinoma of the breast. Breast Cancer Res. Treat. 200, 217\u2013224. https:\/\/doi.org\/10.1007\/s10549-023-06959-3 (2023).","journal-title":"Breast Cancer Res. Treat."},{"key":"5738_CR14","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.21970","volume":"14","author":"I Landry","year":"2022","unstructured":"Landry, I., Sumbly, V. & Vest, M. Advancements in the treatment of triple-negative breast cancer: A narrative review of the literature. Cureus 14, e21970. https:\/\/doi.org\/10.7759\/cureus.21970 (2022).","journal-title":"Cureus"},{"key":"5738_CR15","doi-asserted-by":"publisher","unstructured":"Association, B. c. P. C. o. C. A.-C. & Breast Oncology Group, S. o. O., Chinese Medical Association. Guidelines and guidelines for the diagnosis and treatment of breast cancer of the chinese anti-cancer association (2024 edition). Chin. J. Cancer 33, 1092\u20131187. https:\/\/doi.org\/10.19401\/j.cnki.1007-3639.2023.12.004 (2023)","DOI":"10.19401\/j.cnki.1007-3639.2023.12.004"},{"key":"5738_CR16","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","volume":"15","author":"Y Li","year":"2022","unstructured":"Li, Y. et al. Recent advances in therapeutic strategies for triple-negative breast cancer. J. Hematol. Oncol. 15, 121. https:\/\/doi.org\/10.1186\/s13045-022-01341-0 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"5738_CR17","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1186\/s12885-024-12222-9","volume":"24","author":"Z Liu","year":"2024","unstructured":"Liu, Z. et al. Long-term survival after neoadjuvant therapy for triple-negative breast cancer under different treatment regimens: a systematic review and network meta-analysis. BMC Cancer 24, 440. https:\/\/doi.org\/10.1186\/s12885-024-12222-9 (2024).","journal-title":"BMC Cancer"},{"key":"5738_CR18","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/jco.20.03399","volume":"39","author":"LA Korde","year":"2021","unstructured":"Korde, L. A. et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J. Clin. Oncol. 39, 1485\u20131505. https:\/\/doi.org\/10.1200\/jco.20.03399 (2021).","journal-title":"J. Clin. Oncol."},{"key":"5738_CR19","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1158\/1055-9965.Epi-18-0591","volume":"28","author":"J Xie","year":"2019","unstructured":"Xie, J. & Xu, Z. A population-based study on liver metastases in women with newly diagnosed breast cancer. Cancer Epidemiol. Biomark. Prev. 28, 283\u2013292. https:\/\/doi.org\/10.1158\/1055-9965.Epi-18-0591 (2019).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"5738_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e27837","volume":"10","author":"L Zhang","year":"2024","unstructured":"Zhang, L. et al. A prognostic model for triple-negative breast cancer patients with liver metastasis: A population-based study. Heliyon 10, e27837. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27837 (2024).","journal-title":"Heliyon"},{"key":"5738_CR21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ctrv.2017.10.014","volume":"62","author":"C Wang","year":"2018","unstructured":"Wang, C. et al. Triple negative breast cancer in Asia: An insider\u2019s view. Cancer Treat. Rev. 62, 29\u201338. https:\/\/doi.org\/10.1016\/j.ctrv.2017.10.014 (2018).","journal-title":"Cancer Treat. Rev."},{"key":"5738_CR22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1158\/0008-5472.Can-22-2682","volume":"83","author":"R Bassiouni","year":"2023","unstructured":"Bassiouni, R. et al. Spatial transcriptomic analysis of a diverse patient cohort reveals a conserved architecture in triple-negative breast cancer. Cancer Res. 83, 34\u201348. https:\/\/doi.org\/10.1158\/0008-5472.Can-22-2682 (2023).","journal-title":"Cancer Res."},{"key":"5738_CR23","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1002\/jso.24559","volume":"115","author":"VS Alcantara","year":"2017","unstructured":"Alcantara, V. S., Lim, G. H., Lim, S. H., Sultana, R. & Lee, J. A. Incidence and prognosis of non-metastatic triple negative breast cancer (TNBC) among different races in Southeast Asia. J. Surg. Oncol. 115, 523\u2013537. https:\/\/doi.org\/10.1002\/jso.24559 (2017).","journal-title":"J. Surg. Oncol."},{"key":"5738_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102459","volume":"110","author":"RC Bonadio","year":"2022","unstructured":"Bonadio, R. C. et al. Management of patients with early-stage triple-negative breast cancer following pembrolizumab-based neoadjuvant therapy: What are the evidences?. Cancer Treat. Rev. 110, 102459. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102459 (2022).","journal-title":"Cancer Treat. Rev."},{"key":"5738_CR25","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.3390\/curroncol31070278","volume":"31","author":"H Abahssain","year":"2024","unstructured":"Abahssain, H. et al. Shifting paradigms in TNBC treatment: Emerging alternatives to capecitabine in the post-neoadjuvant setting. Curr. Oncol. 31, 3771\u20133782. https:\/\/doi.org\/10.3390\/curroncol31070278 (2024).","journal-title":"Curr. Oncol."},{"key":"5738_CR26","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1097\/cco.0000000000000893","volume":"34","author":"D Trapani","year":"2022","unstructured":"Trapani, D. et al. Postneoadjuvant treatment for triple-negative breast cancer. Curr. Opin. Oncol. 34, 623\u2013634. https:\/\/doi.org\/10.1097\/cco.0000000000000893 (2022).","journal-title":"Curr. Opin. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-05738-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-05738-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-05738-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T18:29:11Z","timestamp":1751394551000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-05738-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5738"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-05738-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"21 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21666"}}